New drug combo targets Hard-to-Treat cancers

NCT ID NCT06460961

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times

Summary

This early-stage study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 168 adults with various metastatic cancers are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASM METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Atlantic Health System Morristown Medical Center ( Site 4001)

    Morristown, New Jersey, 07960, United States

  • Princess Margaret Cancer Centre ( Site 2001)

    Toronto, Ontario, M5G 2M9, Canada

  • Providence Portland Medical Center ( Site 4002)

    Portland, Oregon, 97213, United States

  • Sheba Medical Center-ONCOLOGY ( Site 3001)

    Ramat Gan, 5265601, Israel

  • South Texas Accelerated Research Therapeutics (START) ( Site 4003)

    San Antonio, Texas, 78229, United States

  • The Alfred Hospital ( Site 1001)

    Melbourne, Victoria, 3004, Australia

  • Westmead Hospital ( Site 1002)

    Westmead, New South Wales, 2145, Australia

Conditions

Explore the condition pages connected to this study.